Momenta Pharmaceuticals (NASDAQ: MNTA) is one of 208 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Momenta Pharmaceuticals to related companies based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, dividends and profitability.

Analyst Recommendations

This is a summary of current recommendations and price targets for Momenta Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Momenta Pharmaceuticals 1 8 0 0 1.89
Momenta Pharmaceuticals Competitors 519 2483 6688 126 2.65

Momenta Pharmaceuticals currently has a consensus price target of $14.44, suggesting a potential upside of 10.26%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.11%. Given Momenta Pharmaceuticals’ peers stronger consensus rating and higher probable upside, analysts clearly believe Momenta Pharmaceuticals has less favorable growth aspects than its peers.


This table compares Momenta Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Momenta Pharmaceuticals -55.61% -16.20% -11.82%
Momenta Pharmaceuticals Competitors -4,120.89% -120.22% -44.25%

Institutional and Insider Ownership

91.2% of Momenta Pharmaceuticals shares are held by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.4% of Momenta Pharmaceuticals shares are held by insiders. Comparatively, 13.7% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Momenta Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Momenta Pharmaceuticals $109.62 million -$21.00 million -16.38
Momenta Pharmaceuticals Competitors $229.36 million -$38.88 million -67.70

Momenta Pharmaceuticals’ peers have higher revenue, but lower earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Momenta Pharmaceuticals has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals’ peers have a beta of 1.49, suggesting that their average share price is 49% more volatile than the S&P 500.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company’s programs include M254, M281 (Anti-FcRn candidate) and M230.

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.